Interventional Glaucoma

Ike Ahmed, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation on the study of standalone multiple trabecular micro-bypass stents for uncontrolled glaucoma at the ASCRS annual meeting in San Diego

Gerd Auffarth, MD, PhD, and the chairman at the Heidelberg University Eye Clinic discussed the 7 year, long-term data for the iStent inject second generation with our team at the 2023 ASCRS meeting in San Diego.

Austin Fox, MD, discussed advancements in contact lens technology and use as part of a careful management strategy during Glaucoma Subspecialty Day at the American Society of Cataract and Refractive Surgery annual conference in San Diego.

Jason Bacharach, MD, presented results at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, highlighting that a large phase 3 clinical trial demonstrated no relevant differences between the 2 formulations.

Eric Mikula, PhD, from ViaLase sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss the company's femtosecond laser image-guided high-precision trabeculectomy, FLigHT, for non-incisional glaucoma treatment at this year's ARVO meeting.

Ophthalmology Times® talked Nevin El-Nimri, MS, OD, PhD, FAAO, about the relationship between optic disc fovea distance, axial length and disc at this year's ARVO meeting.

Glaucoma specialists nationwide reported that glaucoma-related adverse events were common after cataract surgery in children.

Ophthalmology Times® talked with Ronald Zambrano, lab supervisor for the advanced Ophthalmic Imaging Lab at NYU Langone about lamina cribrosa pressure and predicting structural glaucoma progression at this year's ARVO meeting.

Surgeon expects more MIGS, less trabeculectomy.

Body mass index (BMI), central obesity, and the metabolic syndrome may be deciding risk factors in glaucoma.

In a poster presented at the Association for Research in Vision and Ophthalmology, authors Paul S. Kayne, PhD, Alison Obr, PhD, John H. Dodd, PhD, and Carl Spana, PhD, it was demonstrated that PL9588 reduces ocular pressure. Data provides further support for topical administration of melanocortins for ocular inflammation.

Defective calcium clearance is a characteristic feature of early damage to the retinal ganglion cells (RGC) in a mouse model of glaucoma.

Researchers at the Smurfit Institute of Genetics, in collaboration with the biotechnology company Exhaura Ltd., have shown that a gene therapy-based approach can decrease intraocular pressure in pre-clinical models of glaucoma.

Physicians are using the procedure to treat various stages of the disease.

According to the company, the outcomes reported demonstrate a favorable safety profile for its novel, noninvasive glaucoma treatment.

The device is an update on the previous iTrack canaloplasty device and features an ergonomic handpiece.

The first 2023 release of the Video Journal of Cataract, Refractive, & Glaucoma Surgery explores essential techniques for intraocular lens (IOL) removal, providing a diverse range of both routine and novel approaches within its hour-long presentation.

Brimonidine Tartrate Ophthalmic Solution is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma.

GAL-101 is a Phase 2/3-ready small molecule used to treat ophthalmic indications with high unmet medical need.

Ophthalmologists have discussions about driving with glaucoma patients.

Hurdles include limited space, handling thin sclera, choosing the right site.

The company’s MINIject is the only commercially available MIGS implant targeting the supraciliary space.

The researchers from Indiana University School of Medicine found neurons use mitochondria for a steady source of energy, and restoring mitochondrial homeostasis in the diseased neurons can protect the optic nerve cells from being damaged.

The Ergo-Series of the OMNI Surgical System maximizes ergonomics and surgical ease-of-use while continuing to enable surgeons to perform minimally invasive, implant-free glaucoma procedures.

SBI-100 Ophthalmic Emulsion is a synthetic cannabinoid derivative to treat glaucoma and ocular hypertension.